• Wednesday, January 4, 2023 @ 12:00 am

Despite exciting interim results of “Studies 014/015” of evenamide in TRS, Newron trades just above its cash value. Xadago and evenamide are virtually free. Clinical progress of evenamide in schizophrenia and Xadago in PD-LID should add to the value while reducing the clinical development risk. Key catalysts include:

1. Full results “Study 014” of evenamide in TRS (March 2023)
2. Start new label trial Xadago in PD-LID (H1 2023)
3. Results pivotal “Study 008A” of evenamide in non-TRS (H2 2023)

Read full Newron valuation report

You may also be interested in